PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34349829-7	2021	Therefore, we first detected the expression of PAD4 in EPCs of peripheral arterial disease and detected changes in the number and function of endothelial progenitor cells in peripheral blood after injecting the PAD4 inhibitor Cl-amidine into mice.	N-alpha-benzoyl-N5-(2-chloro-1-iminoethyl)-L-ornithine amide	226-236	MMTV LTR integration site 4	Mus musculus	47-51	
26740598-11	2016	PAD4 inhibition by Cl-amidine reduced NETting neutrophils and rescued wound healing in diabetic mice.	N-alpha-benzoyl-N5-(2-chloro-1-iminoethyl)-L-ornithine amide	19-29	MMTV LTR integration site 4	Mus musculus	0-4	
34349829-7	2021	Therefore, we first detected the expression of PAD4 in EPCs of peripheral arterial disease and detected changes in the number and function of endothelial progenitor cells in peripheral blood after injecting the PAD4 inhibitor Cl-amidine into mice.	N-alpha-benzoyl-N5-(2-chloro-1-iminoethyl)-L-ornithine amide	226-236	MMTV LTR integration site 4	Mus musculus	211-215	
34349829-9	2021	The results show that PAD4 is highly expressed in peripheral arterial diseases and the PAD4 inhibitor Cl-amidine can increase the number of EPCs and can treat peripheral arterial diseases by improving the proliferation, migration, and vascularization of EPCs.	N-alpha-benzoyl-N5-(2-chloro-1-iminoethyl)-L-ornithine amide	102-112	MMTV LTR integration site 4	Mus musculus	22-26	
34349829-9	2021	The results show that PAD4 is highly expressed in peripheral arterial diseases and the PAD4 inhibitor Cl-amidine can increase the number of EPCs and can treat peripheral arterial diseases by improving the proliferation, migration, and vascularization of EPCs.	N-alpha-benzoyl-N5-(2-chloro-1-iminoethyl)-L-ornithine amide	102-112	MMTV LTR integration site 4	Mus musculus	87-91